In This Section

Seventh JCA-AACR Special Joint Conference on the Latest Advances in Pancreatic Cancer Research: From Basic Science to Therapeutics

July 8-10, 2022
Brighton Kyoto Hotel
Kyoto, Japan

Extended Abstract Submission DeadlineFriday, June 10, 2022
Extended Registration DeadlineMonday, June 20, 2022

Please note that this meeting will take place as an in-person event in Kyoto, Japan and will also be live-streamed for virtual participation. Visit the meeting website for more information.  

Meeting Website

The JCA and AACR are proud to jointly present this Seventh JCA-AACR Special Joint Conference. This collaboration will bring together basic scientists and clinical researchers from the United States, Japan, and around the world to share the latest and most exciting developments in pancreatic cancer research. The conference will offer ample opportunities for the scientific discussions and interactions that are necessary to make further basic research and clinical progress in the field.

Organizing Committee


JCA

Kohei Miyazono, The University of Tokyo, Tokyo, Japan
Masanobu Oshima,
Kanazawa University Cancer Research Institute, Kanazawa, Japan
Hiroshi Seno,
Kyoto University, Kyoto, Japan

AACR

Elizabeth M. Jaffee, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
Anirban Maitra,
The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Rosalie C. Sears,
Oregon Health & Science University, Portland, Oregon, USA

PROGRAM OVERVIEW:  

  • Keynote Lecture: Pancreatic cancer is PRIMED to become an immunologic disease 
    Elizabeth M. Jaffee, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA 
  • Keynote Lecture: Dissecting pancreatic cancer development with advanced mouse models 
    Yasuhiro Yamada, The University of Tokyo, Tokyo, Japan 
  • Special Session: Patient and Public Involvement 
  • Session 1: Stromal evolution and tumor microenvironment and modeling 
  • Session 2: Inflammation
  • Poster Session 
  • Session 3: Genetics, Kras, p53, and oncogenic signaling 
  • Session 4: Tumor heterogeneity, plasticity, and therapy resistance 
  • Meet-the-Expert Evening Session 
  • Session 5: Screening and early detection, liquid biopsy, biomarkers, and premalignant lesions
  • Session 6: Clinical oncology and targeted therapies 
  • Session 7: Immunotherapy 
  • Session 8: Metabolism, antioxidants, and cachexia 

#JCAaacrPan22